Relationship of Opioid Use and Dosage Levels to Fractures in Older Chronic Pain Patients
- 1.1k Downloads
Opioids have been linked to increased risk of fractures, but little is known about how opioid dose affects fracture risk.
To assess whether risk of fracture increases with opioid dose among older patients initiating sustained use of opioids for chronic non-cancer pain.
A cohort study that uses Cox proportional hazards models to compare fracture risk among current opioid users vs. persons no longer using opioids.
Members of an integrated health care plan (N = 2,341) age 60 years and older who received 3+ opioid prescriptions within a 90-day period for chronic, non-cancer pain between 2000 and 2005.
Time-varying measures of opioid use and average daily dose in morphine equivalents were calculated from automated data. Fractures were identified from automated data and then validated through medical record review.
Compared with persons not currently using opioids, opioid use was associated with a trend towards increased fracture risk (1.28 (95% CI (0.99, 1.64 )). Higher dose opioid use (≥50 mg/day) was associated with a 9.95% annual fracture rate and a twofold increase in fracture risk (2.00 (95% CI (1.24, 3.24)). Of the fractures in the study cohort, 34% were of the hip or pelvis, and 37% were associated with inpatient care.
Higher doses (≥50 mg/day) of opioids for chronic non-cancer pain were associated with a 2.00 increase in risk of fracture confirmed by medical record review. Clinicians should consider fracture risk when prescribing higher-dose opioid therapy for older adults.
KEY WORDSfracture opioids elderly survival chronic pain
This research was supported by a grant to Dr. Michael Von Korff from the National Institute of Drug Abuse [DA022557].
Conflict of Interest Statement
Ms. Saunders owns stock in for-profit companies. Dr. Von Korff owns stock in for-profit companies and has received a grant from Johnson & Johnson. In the past three years Dr. Sullivan has received grants from Wyeth, Eli Lilly and Company, Aetna, and Ortho McNeil and has consulted for Eli Lilly and Company. Otherwise, the authors report no conflicts of interest.
- 8.Paulose-Ram R, Hirsch R, Dillon C, Losonczy K, Cooper M, Ostchega Y. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf. 2003;12:315–26.CrossRefPubMedGoogle Scholar
- 19.Abrahamsen B, Brixen K. Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk. Osteoporosis Int. 2008; Aug 9 [Epub ahead of print].Google Scholar
- 22.Saunders K, Davis R, Stergachis A. Group Health Cooperative. In: Strom B, ed. Pharmacoepidemiology. West Sussex: John Wiley and Sons; 2005:223–39.Google Scholar
- 26.Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer-Verlag; 2000.Google Scholar
- 31.AGS Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc (in press).Google Scholar